Stevanato Group has expanded its drug delivery portfolio with Deora™, a multi-use, fixed-dose pen injector platform designed to simplify self-administration while supporting the growing demand for injectable therapies such as diabetes, obesity and other chronic disease treatments. The platform addresses a key gap between single-use autoinjectors and variable-dose pen injectors by combining ease of use with manufacturing efficiency and sustainability.
- Today is: